Abstracts tagged "autologous transplantation"

Abstract Number: 879 • 2014 ACR/ARHP Annual Meeting
Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis: Prolonged Remission of Disease Activity in a Long-Term Follow up
Eleonora Zaccara¹, Domenico Sambataro², Wanda Maglione¹, Gianluca Sambataro¹, Francesco Onida³, Claudio Annaloro³, Giorgia Saporiti³, Elena Tagliaferri³, Agostino Cortelezzi³, Rosaria Giordano⁴, Claudio Vitali⁵ and Nicoletta Del Papa², ¹U.O.C. Day Hospital Reumatologia, Osp. G. Pini, Milano, Italy, ²Rheumatology Unit, Istituto G.Pini, Milan, Italy, ³Hematology-BMT Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, ⁴Franco Calori Cell Factory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, ⁵Sezione Reumatologia, Istituto San Giuseppe, Lecco, Italy
Background/Purpose In the recent years, autologous haematopoietic stem cell transplantation (AHSCT) has been shown to represent an effective therapeutic option for patients (pts) suffering from…
Abstract Number: 686 • 2012 ACR/ARHP Annual Meeting
Cell-Type Specific Type I Interferon Signatures in Autologous Stem Cell Transplanted Lupus Patients: Different Molecular Behavior Between CD4+ T Cells and Monocytes
Chieko Kyogoku¹, Joachim R. Grün¹, Tobias Alexander², Robert Biesen³, Falk Hiepe⁴, Thomas Häupl³, Andreas Radbruch¹ and Andreas Grützkau¹, ¹German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ⁴Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that affects multiple organs, whose pathology is mainly caused by the augmented interferon (IFN)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].